Viyash Scientific Limited has completed the allotment of 8,000 equity shares under its Employee Stock Option Plan 2020 to eligible employees. The Nomination and Remuneration Committee approved this allotment through a resolution passed by circulation on April 28, 2026.

ESOP Allotment Details

The company allotted the equity shares at a predetermined exercise price, providing employees with an opportunity to acquire company ownership. The allotment represents the exercise of stock options granted under the SeQuent ESOP 2020 scheme.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued and paid-up equity share capital. The newly allotted shares will carry the same rights and privileges as existing equity shares of the company.

Share Rights and Ranking

The newly allotted equity shares will rank pari passu in all respects with the existing equity shares of the company. This means the new shares will have equal rights regarding dividends, voting, and other corporate benefits.

Corporate Compliance

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, has duly informed the stock exchanges about this allotment in compliance with regulatory requirements. The company secretary and compliance officer has signed the disclosure, ensuring proper adherence to corporate governance norms.

Viyash Scientific has announced significant board changes with the appointment of two Additional Non-Executive, Non-Independent Directors representing the Carlyle group, along with revisions to its Employee Stock Option Scheme. The appointments were made based on recommendations from the Nomination and Remuneration Committee and approved during a board meeting held on April 22, 2026.

Dual Board Appointments

The company's Board of Directors approved the appointment of two senior executives from Carlyle group as Additional Directors with effect from April 22, 2026. Both appointments are subject to shareholder approval and the directors are liable to retire by rotation.

Professional Backgrounds

Amit Jain's Experience

Amit Jain serves as Partner and Head of Carlyle India Advisors, overseeing Carlyle's India operations and private equity team. He leads investment and portfolio company activities across technology, consumer, advanced manufacturing and industrial sectors. Jain joined Carlyle in 2021 after a decade at Blackstone India, where he served as Senior Managing Director in the Private Equity Group.

His career began with consulting at McKinsey & Company and operating roles at Unilever in India. He currently serves on the boards of several Carlyle portfolio companies, including Quest Global, Piramal Healthcare, VLCC, Highway Roop, Varmora Granito, and Strata Geosystems, Knack Global & Adastrra. Jain was recognized by The Economic Times as one of India's "40 Under 40" young business leaders in 2019.

Abhiroop Jayanthi's Profile

Abhiroop Jayanthi is a Managing Director and member of the Asia Private Equity team at Carlyle, which manages USD 465 billion of assets under management. He advises on investments in India focusing on healthcare, life sciences, advanced manufacturing, and industrial sectors.

With 15 years of private equity experience, Jayanthi previously served as Managing Director at Bain Capital, leading investments across healthcare, life sciences, technology, and industrials sectors. He was named one of India's most promising young corporate leaders by The Economic Times in 2014. Jayanthi holds an MBA from the Wharton Business School and earned his undergraduate degree in Industrial Engineering from IIT Delhi.

ESOP Pool Revision

The Board approved a revised Employee Stock Option Scheme pool under ESOP 2026. The total number of stock options was adjusted from the originally proposed 1,34,75,000 to 1,30,98,000 stock options based on the recommendation of the Nomination and Remuneration Committee.

Strategic Significance

The appointment of both directors represents Carlyle group's continued involvement in Viyash Scientific's governance structure. According to the regulatory filing, both appointees have declared they are not debarred from holding director positions pursuant to any SEBI order or other authority. The Board meeting was conducted from 11:30 a.m. to 12:39 p.m. on April 22, 2026, with the company fulfilling its disclosure obligations under Regulation 30 of the SEBI Listing Regulations.